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Angelman syndrome is a severe neurodevelopmental disorder caused by mutations in UBE3A.
Sunet al. (2015) reportSK2asaUBE3Asubstrateandprovide insight into themolecularmechanisms
that might underlie impaired neuronal function in individuals affected by Angelman syndrome.Angelman syndrome (AS) affects some-
where from 1 in 10,000 to 1 in 20,000 peo-
ple (Bird, 2014). This neurodevelopmental
disorder is characterized by an unusually
happy demeanor, severe intellectual
disability, speech impairment, ataxia,
and refractive epilepsy and may be asso-
ciated with autistic symptoms (Bird,
2014). AS is caused by deletions or point
mutations involving the maternally in-
herited copy of UBE3A, which encodes
a HECT domain-containing ubiquitin E3
ligase (Jiang et al., 1999; Margolis et al.,
2015; Mabb and Ehlers, 2010). The cova-
lent addition of ubiquitin to a lysine resi-
due in targeted proteins regulates their
localization, stability, endocytosis, and
function (Mabb and Ehlers, 2010). Mouse
models for AS exhibit impaired learning
and memory, defects in dendritic spine
morphology, reduced hippocampal long-
term potentiation (LTP), and deficiencies
in experience-dependent cortical plas-
ticity (Yashiro et al., 2009). Despite the
importance of UBE3A in neuronal devel-
opment and function, only a limited num-
ber of UBE3A neuronal substrates have
been identified (Greer et al., 2010; Margo-
lis et al., 2010). In this issue of Cell Re-
ports, Sun et al. shine a bright light on
the molecular mechanisms underlying
UBE3A-dependent synaptic plasticity,
learning, and memory. Using a multi-
pronged approach, they demonstrate
that SK2 (small-conductance Ca+2-acti-
vated K+ channel 2) is a substrate of
UBE3A, suggesting that UBE3A might
regulate cognitive function through SK2.Their findings also identify a potential ther-
apeutic approach for the treatment of AS.
Calcium (Ca+2) signaling is essential
for synaptic activity. SK channels are
potassium channels that are activated
by increased submicromolar concentra-
tions of intracellular Ca+2. These channels
(SK1, SK2, and SK3) are widely ex-
pressed in the CNS, where they modulate
synaptic transmission and the induction
of synaptic plasticity to impact learning
and memory (Adelman et al., 2012). SK
channels are therefore extremely impor-
tant for normal cognitive function. SK2
is a postsynaptic multiprotein complex
that contains four pore-forming subunits
and constitutively bound calmodulin
(CaM), protein kinase CK2, and protein
phosphatase A2 (PP2A) (Adelman et al.,
2012). In hippocampal pyramidal neu-
rons, SK2 regulates neuronal excitability
and the threshold for LTP induction (Adel-
man et al., 2012). However, very little
is currently known about how SK2 locali-
zation and function are regulated at the
synapse.
Using a variety of in vitro and in vivo ap-
proaches, Sun et al. show that UBE3A-
deficient (AS) mice have increased levels
of SK2 at the synapse (Sun et al., 2015).
The specific increase of SK2 in dendritic
structures does not correspond to a
global increase in SK2 expression;
instead, the direct interaction between
SK2 and UBE3A suggests that SK2 levels
may be regulated by ubiquitin-mediated
degradation or endocytocis. In fact, SK2
ubiquitination is significantly decreasedCell Reportin AS animals in comparison to controls.
Ubiquitination of the SK2 C-terminal
domain is mediated by UBE3A activity at
lysine residues K506, K515, and K550
downstream of the CaM binding site.
More importantly, UBE3A-mediated ubiq-
uitination at these residues regulates the
surface expression and endocytosis of
SK2 in hippocampal neurons.
AS mice have impaired LTP, which
has been linked to increased internali-
zation of a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptors
(AMPARs); this increased internalization
is caused in part by increased levels
of the synaptic protein ARC, a substrate
of UBE3A in vitro (Greer et al.,
2010). UBE3A-mediated degradation of
Ephexin5 promotes the development
of excitatory synapses, suggesting an
additional mechanism through which syn-
aptic plasticity and transmission might
be affected in AS-affected individuals
(Margolis et al., 2010). SK2 channels
have previously been shown to modulate
the induction of synaptic plasticity, and
blocking SK2 channels with its specific
inhibitor, Apamin, was shown to facilitate
induction of LTP in CA1 hippocampal
neurons (Adelman et al., 2012). Sun et al.
now show that theta-burst stimulation
(TBS)-induced LTP is dependent on SK2
activity in ASmice. Acute exposure of hip-
pocampal slices to Apamin restores TBS-
LTP levels in AS hippocampal slices to
levels similar to those in wild-type slices.
The importance of UBE3A-mediated
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is further shown in vivo by treatment of
wild-type animals with a SK2 peptide
containing K550, given that wild-type
animals treated with this peptide mimic
the LTP impairment in AS mice. Similar
approaches to the ones described
above reveal that long-term depression
(LTD), an activity-dependent reduction in
synaptic strength important for learning
and memory, is also impacted by SK2
function in AS mice. LTP and LTD cellular
processes require the activation of
AMPARs and N-methyl-D-aspartate re-
ceptors (NMDARs) at the synapse, and
SK2 is activated by Ca+2 release after
NMDAR activation, resulting in the
reduction and/or blockage of NMDAR-
dependent Ca+2 signaling (Adelman
et al., 2012). Here, pharmacological isola-
tion of NMDAR function—either by block-
ing AMPARs with CNQX or by use of the
AP5-a NMDAR antagonist—shows that
SK2-dependent LTP and LTD defects in
AS mice require NMDAR function.
The relevance of SK2 function to
learning and memory is highlighted by
the fact that Apamin treatment of wild-
type animals enhances their performance
in the water-maze learning test (Adelman
et al., 2012). Building on these molecular
and physiological findings, the authors360 Cell Reports 12, July 21, 2015 ª2015 Theprobe further into the role of SK2 in
AS-associated cognitive impairments by
conducting behavioral analysis. Context-
dependent fear-conditioning paradigms
are severely compromised in AS mice,
and treatment of AS mice with Apamin
leads to a significant improvement in
context- and cue-dependent learning.
These findings represent a significant
advancement in our understanding of
the underlying mechanisms that control
cognitive impairment in individuals with
AS and identifies a potential therapeutic
target for treatment.
Like a symphony conductor, UBE3A-
mediated endocytosis of postsynaptic
proteins carefully orchestrates the func-
tion of multiple synaptic pathways that
are important for learning and memory.
On the basis of the similarities between
Apamin and BDNF effects on learning
and memory (Adelman et al., 2012), as
well as reported defects in BDNF-TrkB
signaling in AS (Cao et al., 2013), one
might someday ask, ‘‘What is the
potential link between SK2 and BDNF
signaling in AS pathophysiology?’’ By
identifying SK2 as a target of UBE3A,
this study unveils a new aspect of the
molecular pathology in AS, which will
lead to new lines of investigation withAuthorsrelevance to disease treatment and
cognition.
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